P1736: CHARACTERISTICS, HEALTHCARE UTILIZATION, AND COSTS ASSOCIATED WITH INOTUZUMAB OZOGAMICIN, BLINATUMOMAB, OR OTHER AGENTS FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA

Authors: A. Russell-Smith, R. Shah, A. Silverstein, A. Petrilla, B. Leinwand, D. Norris, A. Schroeder

Published: 2022-06-24

DOI: 10.1097/01.hs9.0000849800.15938.16

Source: Full article

---

Abstract

No abstract found.